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Purpose: Simponi® (golimumab, MSD) is a fully human monoclonal antibody against tumor 
necrosis factor alpha administered subcutaneously using an autoinjector or a prefilled syringe. 
This study examined preference for administration of golimumab by autoinjector or prefilled 
syringe in patients with moderate-to-severe ulcerative colitis (UC).
Patients and methods: This was a multicenter, open-label, randomized crossover trial 
(EudraCT no 2014-000656-29). Patients with moderate-to-severe UC were randomized 1:1 
to receive 2 subcutaneous injections of 50 mg golimumab with the autoinjector followed by 
2 injections of 50 mg with the prefilled syringe or the same 4 injections administered in the 
opposite order. Patients assessed preference, ease of use, and discomfort immediately after the 
injections and 2 weeks later.
Results: Ninety-one patients were included (median age=42.7 years [range, 19.7–93.7]; 58% male). 
The autoinjector was preferred by 76.9% of patients immediately after injections and by 71.4% 
2 weeks later. The autoinjector was more often considered extremely easy or easy to use (94.5%) 
than the prefilled syringe (73.6%). Moderate discomfort or worse was reported by more patients 
when using the prefilled syringe (20.9%) than when using the autoinjector (5.5%), and severe 
discomfort or discomfort preventing injection of future doses was reported by 8.8% for the pre-
filled syringe but not at all when using the autoinjector. A favorable or extremely favorable overall 
impression was reported by 89.0% for the autoinjector and 72.5% for the prefilled syringe.
Conclusion: Most patients with moderate-to-severe UC preferred to self-administer golimumab 
with the autoinjector over a prefilled syringe.
Keywords: autoinjector, adherence, anti-TNF, subcutaneous injection, treatment, self-
injection
Introduction
Ulcerative colitis (UC) is a chronic and incurable autoimmune inflammatory bowel 
disorder characterized by continuous inflammation and ulceration of the mucosa of 
the rectum and, to a variable extent, the colon.1,2 The disease affects 2.5 million people 
worldwide and is usually diagnosed when individuals are in their 20s and peaks again in 
their 60s or 70s, but it can occur at any age. UC is generally characterized by flares that 
alternate with periods of remission, although some patients have continuous activity. 
The severity of flares and their response to treatment are difficult to predict, although 
the frequency of flares decreases with time. Between 25% and 40% of people living 
with UC will require surgery at some point in their life.1
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Simponi® (golimumab, MSD, Janssen Biotech, Inc., 
Horsham, PA, USA) is a fully human monoclonal antibody 
against tumor necrosis factor α (TNF-α) available in the 
European Union since 2013 for the treatment of moderate-
to-severe active UC in adult patients who have had an 
inadequate response to conventional therapy or who are 
intolerant to or have medical contraindications for such 
therapies.3 Golimumab is also indicated for the treatment 
of moderate-to-severe active rheumatoid arthritis (RA) (in 
combination with methotrexate), active psoriatic arthritis 
(alone or in combination with methotrexate), and active 
ankylosing spondylitis.
Golimumab is administered with the SmartJect® autoin-
jector (MSD, Janssen Biotech, Inc.) or with a prefilled syringe 
(Figure 1). The SmartJect autoinjector was developed to sim-
plify self-injection of golimumab for patients suffering from 
RA, psoriatic arthritis, and ankylosing spondylitis, with the 
objective of optimizing treatment adherence.4 Autoinjectors 
offer several advantages, including portability, convenience, 
and flexible scheduling, and they have been shown to improve 
treatment adherence.5–7 In the GO-MORE study, which exam-
ined the efficacy and safety of golimumab in biologic-naive 
RA patients, two-thirds of those who self-injected chose to 
use the autoinjector over a prefilled syringe.4 In addition, 
most of the patients using the autoinjector had a favorable 
impression of it, considered it easy to use, and reported that 
it caused little pain or discomfort. Device preferences for 
UC patients, however, have not been reported and may be 
different from RA patients who often suffer from hand pain, 
swelling, and deformities. Here, we report the results of a 
study examining whether patients with moderate-to-severe 
UC prefer administration of golimumab using the SmartJect 
autoinjector or a prefilled syringe.
Patients and methods
Study design
This was a multicenter, open-label, randomized, crossover 
trial comparing preference for administration of golimumab 
using the SmartJect autoinjector or a prefilled syringe in 
patients with moderate-to-severe UC (EudraCT no 2014-
000656-29). The trial was conducted at 20 sites in Belgium 
(19 sites recruited patients) between July 2014 and October 
2015. The primary objective was to determine whether 
UC patients prefer to administer golimumab using the 
autoinjector, using a prefilled syringe, or are undecided. 
Secondary objectives were to determine which of the 2 
administration devices patients consider the easiest to use and 
result in the least discomfort, and how patient characteristics 
influence device preference.
The study included adults with an established diagnosis 
of UC and moderate-to-severe disease (Mayo score $6, 
including an endoscopic subscore $2) and a previous con-
ventional therapy of at least 3 months with aminosalicylates 
and at least 3 months with corticosteroids, 6-mercaptopurine, 
or azathioprine unless intolerant to or contraindicated for 
such therapies. Individuals who previously self-injected 
any agent or who were using other biological agents were 
excluded.
Patients completed a questionnaire to collect demo-
graphic data, and investigators collected information about 
the patient’s medical history. Patients were then randomized 
1:1 to receive 2 injections of golimumab 50 mg (Simponi®, 
MSD) with the autoinjector (SmartJect®, MSD) followed by 
2 injections of 50 mg with the prefilled syringe or 2 injections 
of 50 mg golimumab with the prefilled syringe followed by 
2 injections with the autoinjector (total 200 mg golimumab 
administered). All injections were subcutaneous, were in the 
same part of the body, and were performed on the same day 
(day 0). The first of the 2 injections with each device was 
performed by the physician, and the second by the patient 
under the physician’s supervision.
Immediately after using each device, patients answered 
a questionnaire assessing the hand used to self-inject (left, 
right, both), ease of use for self-injection (extremely easy, 
easy, neither easy nor difficult, difficult, or extremely dif-
ficult), overall discomfort (none, mild, moderate, severe, 
Figure 1 Golimumab injection devices.































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Patient preference for golimumab injection device
or such discomfort that I cannot inject future doses), and 
overall impression of the self-injection experience (extremely 
favorable, favorable, neither favorable nor unfavorable, 
unfavorable, or extremely unfavorable). After completing 
all 4 injections, patients completed a questionnaire on their 
preference for the devices (prefilled syringe, autoinjector, 
or undecided). After 2 weeks, the patient was contacted to 
complete the device preference questionnaire again to capture 
the effect of any delayed adverse events on the patient’s 
responses.
Investigators recorded adverse events according to the 
International Conference on Harmonization Guidelines for 
Good Clinical Practice including the following: adverse 
event/diagnosis; dates of onset and resolution; severity 
(mild, moderate, severe), whether the event was serious 
(yes/no) and, if so, why; potential relationship to the study 
drug (yes/no); and action taken. Adverse events were consid-
ered serious if they resulted in death, were life threatening, 
required hospitalization or prolongation of an existing inpa-
tient hospitalization, resulted in a persistent or significant 
disability or incapacity, were a congenital abnormality or 
birth defect, were cancer, were associated with an overdose, 
or were any other important medical event.
ethics
The study was approved by each site’s independent ethics 
committee (Table S1) and was conducted in accordance 
with International Conference on Harmonization Guideline 
for Good Clinical Practice. All included patients provided 
written informed consent.
Study size estimate
A power calculation was not performed. Instead, a study 
size estimate of 100 subjects was planned based on sample 
sizes that yielded relevant results in similar studies.8–11 
Assuming 10% dropout, approximately 110 subjects were 
to be screened.
Statistical analysis
The primary outcome measure (device preference) was 
analyzed in the per-protocol set, defined as all subjects 
who met the inclusion and exclusion criteria, received all 
4 injections, and completed the device preference question-
naire. Statistical analyses of preference included frequency 
distribution overall immediately and 2 weeks after injection; 
by order of device administration; 2 weeks after injection 
by preference immediately after injection; and by age, sex, 
ethnicity, marital status, education level, employment status, 
and total Mayo score category. Statistical analysis of second-
ary outcome measures (ease of use, discomfort, and overall 
impression) included frequency distribution overall and by 
order of injection. As stipulated in the study protocol, only 
descriptive statistics were calculated, although in a post hoc 
analysis, preferences were analyzed according to subject 
baseline characteristics by Cochrane–Armitage trend test 
or Fisher’s exact test, with p-values below 0.05 considered 
to indicate statistical significance. Missing data were not 
replaced. Calculations were made using SAS version 9.2 
(SAS Institute, Cary, NC, USA).
Results
Patients
Between July 11, 2014, and September 17, 2015, 100 patients 
were included in the study, and the study was completed 
on October 5, 2015. Of the 100 recruited patients, 99 were 
treated. Another 8 patients did not fulfill the selection criteria. 
Thus, 91 patients were included in the analysis. Most of these 
patients were between 30 and 60 years of age, slightly more 
than half were male, and all but 2 were White/Caucasian 
(Table S2). On average, patients had been diagnosed with 
UC for 8.6 years. Disease severity was moderate in about 
two-thirds and severe in about one-third, although precise 
proportions depended slightly on the assessment (Mayo 
score, physician’s global assessment, and sigmoidoscopic 
and endoscopic findings). Most were being treated with 
5-aminosalicylic acid and corticosteroids, and most had not 
previously received anti-TNF therapy.
Device preference
Immediately after injections, approximately three-quarters 
of patients (76.9%) indicated that they preferred administer-
ing golimumab with the autoinjector (Figure 2). This was 
similar to the preference reported 2 weeks later, with 71.4% 
reporting that they preferred the autoinjector. This was also 
the case irrespective of the order of injection, although 
more patients who started with the autoinjector preferred it 
(84.4%) than patients who started with the prefilled syringe 
(69.6%). Also, most patients (92.3%) did not change their 
preference 2 weeks later: of those who preferred a prefilled 
syringe immediately after the injections, all still preferred 
it 2 weeks later, and of those that preferred the autoinjector 
immediately after the injections, 92.9% still preferred it 
2 weeks later. Results were similar when analyzed for all 
99 patients completing the questionnaire (data not shown). 
A post hoc analysis showed that preference for the autoin-
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severity as measured by the total Mayo score, sex, marital/
cohabitation status, level of education, employment status, 
or time since UC diagnosis (data not shown).
ease of use, discomfort, and overall 
impression of the devices
More patients considered the autoinjector extremely easy 
or easy to use (94.5%) than the prefilled syringe (73.6%) 
(Table 1). Moderate discomfort or worse was reported by 
only 5 patients (5.5%) when using the autoinjector but by 
19 patients (20.9%) when using the prefilled syringe. Severe 
discomfort or discomfort such that the patient could not inject 
future doses was reported by 8 patients (8.8%) when using the 
prefilled syringe but was not reported by any of the patients 
using the autoinjector.
In agreement with these findings, 89.0% of patients had 
an overall extremely favorable or favorable impression of 




























































































Figure 2 Device preference.
Notes: Patient preference for the different devices was assessed immediately after the injections and 2 weeks later. (A) Device preference according to order of presentation 
immediately after the injections. (B) Device preference according to order of presentation 2 weeks after the injections. (C) Device preference at week 2 according to 
preference immediately after the injections. (D) Device preference immediately after the injections according to age group. (E) Device preference immediately after the 
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Patient preference for golimumab injection device
favorable impression of the prefilled syringe. An unfavorable 
impression of the device or worse was reported by only 
2 patients (2.2%) when using the autoinjector but by 
8 patients (8.8%) when using the prefilled syringe.
The order of use of the 2 different devices appeared to 
slightly bias the subjects toward the device they used first. For 
example, the proportion of patients with an extremely favor-
able or favorable impression of the autoinjector was 93.3% 
when it was used first vs 84.8% when it was used second. Like-
wise, the proportion of patients with an extremely favorable or 
favorable impression of the prefilled syringe was 84.8% when 
it was used first vs 60.0% when it was used second.
Safety
None of the patients experienced a serious adverse event. 
Treatment-emergent adverse events, all mild or moderate in 
severity, were reported by 10 patients (10.1%) (Table S3). 
These events included injection-site hematoma (n=2), 
injection-site pain (n=1), palpitations (n=1), UC flare (n=1), 
dyspepsia (n=1), flatulence (n=1), hemorrhoidal hemor-
rhage (n=1), tooth sensitivity (n=1), parotid gland enlarge-
ment (n=1), viral upper respiratory tract infection (n=1), 
headache (n=1), and hot flush (n=1).
Discussion
This study showed that most patients with moderate-to-
severe UC preferred to self-administer golimumab with 
the autoinjector over a prefilled syringe. More patients 
found the autoinjector easier to use and to less often cause 
discomfort than the prefilled syringe. This preference for the 
autoinjector did not change when measured again 2 weeks 
later, during which time most delayed reactions would have 
appeared. Demographic characteristics did not significantly 
affect preference. Order of presentation did not affect the 
overall preference for the autoinjector, although it biased 
the preference somewhat toward the device first presented. 
The results of this study are strengthened by the fact that data 
were collected in a real-life clinical setting at multiple sites. 
In addition, although the absolute sample size was small, this 
study included a relatively large population for UC and was 
enough to observe meaningful differences in preference.
Overall opinions were also favorable in the GO-MORE 
trial, in which patients with active RA self-injected or had 
someone else administer subcutaneous golimumab with the 
same device.4 Although individuals with RA often suffer 
from hand pain, swelling, and deformities, in GO-MORE, 
two-thirds of patients who chose to self-inject selected the 
autoinjector over a prefilled syringe. Most of the patients in 
the GO-MORE study who used the autoinjector had a favor-
able impression of it, considered it easy to use, and reported 
that it caused little pain or discomfort. However, the study 
did not directly assess preference or compare patient experi-
ences between the autoinjector and injection with the prefilled 
syringe. A preference for the golimumab autoinjector over 
previous injection devices was also reported by 70.6% of 
patients in the GO-SAVE trial, which included patients with 
active RA who were switched from adalimumab or etanercept 
to golimumab.12
Table 1 ease of use, discomfort, and overall impression of the devices










ease of use of 
self-injection
Extremely easy 27 (60.0) 26 (56.5) 53 (58.2) 9 (20.0) 15 (32.6) 24 (26.4)
Easy 17 (37.8) 16 (34.8) 33 (36.3) 20 (44.4) 23 (50.0) 43 (47.3)
Neither easy nor difficult 1 (2.2) 1 (2.2) 2 (2.2) 11 (24.4) 5 (10.9) 16 (17.6)
Difficult 0 (0.0) 1 (2.2) 1 (1.1) 2 (4.4) 1 (2.2) 3 (3.3)




no discomfort 27 (60.0) 29 (63.0) 56 (61.5) 11 (24.4) 24 (52.2) 35 (38.5)
Mild discomfort 17 (37.8) 13 (28.3) 30 (33.0) 20 (44.4) 17 (37.0) 37 (40.7)
Moderate discomfort 1 (2.2) 4 (8.7) 5 (5.5) 9 (20.0) 2 (4.3) 11 (12.1)
severe discomfort 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.7) 0 (0.0) 3 (3.3)
such discomfort that i 
cannot inject future doses






Extremely favorable 17 (37.8) 26 (56.5) 43 (47.3) 8 (17.8) 18 (39.1) 26 (28.6)
Favorable 25 (55.6) 13 (28.3) 38 (41.8) 19 (42.2) 21 (45.7) 40 (44.0)
Neither favorable nor 
unfavorable
3 (6.7) 5 (10.9) 8 (8.8) 13 (28.9) 4 (8.7) 17 (18.7)
Unfavorable 0 (0.0) 2 (4.3) 2 (2.2) 3 (6.7) 1 (2.2) 4 (4.4)
Extremely unfavorable 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.4) 2 (4.3) 4 (4.4)
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Prefilled pens or other autoinjectors are also preferred 
over and considered easier to use and less painful than 
syringes for self-administration of darbepoetin by chronic 
kidney disease patients,11 methotrexate13 and adalimumab14 
for RA patients, and insulin for diabetes patients.15–18 Simi-
larly, a study in healthy volunteers found that subcutaneous 
injection by autoinjector was preferred over syringe injection 
by a nurse.19
A systematic review in 2013 found that treatment adher-
ence to anti-TNF biologics in UC patients was only 52.7%.20 
It also found that administration with a syringe vs a pen was 
a predictor of nonadherence. Although the SmartJect autoin-
jector might therefore be expected to improve adherence to 
golimumab, we did not assess adherence in this study.
Conclusion
This study showed that patients with UC generally prefer to 
administer golimumab with an autoinjector. Although this 
should help inform prescribers about what their patients may 
expect, they should be aware that some patients might still 
prefer using a prefilled syringe.
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email sdeneve@hhr.be October 2014 Page 2
Sint Augustinus (GZA Ziekenhuizen) 
Commissie Medische Ethiek 
Professor Bart Van den Eynden 
Sint-Vincentiusstraat 20 
2018 Antwerpen 




Zol Genk, Campus St Jan 
Comité Medische Ethiek 
Doctor Patrick Noyens 
schiepse Bos 6 
3600 genk 
Tel: 089 32 16 02 Fax 089 32 79 00 
email ec.submission@zol.be 
AZ ST Jan Brugge 
Commissie Medische Ethiek 
Doctor Ludo Vanopdenbossch 
ruddershove 10 
8000 Brugge 
Tel: 050 45 99 42 Fax 050 45 30 57 
email ethisch.comite@azsintjan.be 
UCL St Luc 
Commission d’Ethique Biomédicale Hospitalo-Facultaire 
de l’UCL 
Professor J.M. Maloteaux 
Avenue Hippocrate 55.14, Tour Harvey, niveau 0 
1200 Bruxelles 
Tel: 02 764 55 14 Fax 02 764 55 13 
email commission.ethique@md.ucl.ac.be 
CHC St Joseph Liège 
Comité d’ethique médicale des cliniques St Joseph 
Doctor rené stevens 
Rue de Hesbaye 75 
4000 Liège 
Tel: 04 224 89 90 Fax 04 229 89 92 
email rene.stevens@chc.be 
La citadelle de Liège 
Comité d’ethique médicale 
Professeur François DAMAS 
Boulevard du 12ème de Ligne, 1 
4000 Liège 
Tel: 04 225 69 35 Fax 04 225 76 41
email marie.louise.frenay@chrcitadelle.be 
OLV ziekenhuis Aalst 
Ethisch Comité OLV Ziekenhuis 
Doctor Antoon leloup 
Moorselbaan 164 
9300 Aalst 




Prof. Dr. André herchuelz 
route de lennik 808 
1070 Bruxelles 
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Patient preference for golimumab injection device
Table S1 (Continued)
GHDC, Saint-Joseph, Charleroi 
Comité d’Ethique Hospitalier, Grand Hopital de Charleroi 
Mrs Laurence Gillard 
Grand Rue 3 
6000 charleroi 
Tel: 071 10 43 30 Fax 071 10 85 96 
email duthoy.audrey@ghdc.be 
ZNA Jan Palfijn Antwerpen 
Dr. P.P. De Deyn 
Commissie voor Medische Ethiek ZNA 
ZNA Koningin Paola Kinderziekenhuis (P6- lokaal 617) 
lindendreef 1, 
2020 Antwerpen 
Tel: 03/280.34.29 of 03/280.34.28 Fax 03/280.30.60 
email ethische.commissie@zna.be 
Centre Hospitalier de Wallonie picarde – CHwapi A.S.B.L. 
Site Union 
Dr. luc Desplanque 
Comité d’Ethique 
39, Boulevard Lalaing 
7500 Tournai 
Tel: 069 33 17 56 Fax 069 25 86 54
email luc.desplanque@chwapi.be/ nathalie.mat@chwapi.be 
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Virga Jesse ziekenhuis, Hasselt 
Dr. Koen Magerman 
Ethische Toetsingscommissie Virga Jesse 
stadsomvaart 11 
3500 hasselt 
Tel: 011/30.91.11 Fax 011/30.91.18 
email ethische.toetsingscommissie@virgajesse.be 
chr Peltzer la Tourelle 
Dr. hassan Kalantari 
Comité d’Ethique 
rue du Parc 29 
4800 Verviers 
Tel: 087/21 21 71 Fax 087/21.21.39 
email comite.ethique@chplt.be 
AZ Sint Maarten 
Dr. J. Vander Sande 
Ethisch comité van vzw Emmaüs 
Edgard Tinellaan 1c 
2800 Mechelen 
Tel: 015/44 67 21 Fax 015 44 67 10 
email brigitte.van.looy@emmaus.be 
AZ Damiaan




Tel: 050 41 40 67 Fax 050 41 40 78 
email mbrusselle@azdamiaan.be 
(Continued)
Table S2 Patient demographic characteristics
Characteristic Value
Number included in the per-protocol analysis 91
Age (years)








Marital status, n (%)
Single 23 (25.3)
Married/living together 67 (73.6)
Widow 1 (1.1)
Highest education level, n (%)
Primary education 6 (6.6)
Vocational secondary education 13 (14.3)
Technical secondary education 13 (14.3)
General secondary education – humanities 12 (13.2)
Higher education (graduate/nonuniversity) 30 (33.0)
Higher education (university) 17 (18.7)
Professional status, n (%)
student 9 (9.9)
Working full time 48 (52.7)
Working part time 11 (12.1)
Not working 23 (25.3)
Time since UC diagnosis (y)
Mean (SD) 8.6 (8.8)
Range 0.0–38.1




Primary sclerosing cholangitis 3 (3.3)
Other 6 (6.6)
Previous exposure to anti-TNF, n (%)
naive 76 (83.5)
experienced 15 (16.5)
concomitant medications, n (%)







Dr. Rob Schildermans 
Ethische Commissie 
AZ St Lucas Brugge 
Sint-Lucaslaan 29 
8310 Brugge 
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Mean (SD) 8.8 (1.6)
Min, max 6, 12




Stool frequency, n (%)
normal 0 (0.0)
1–2 stools more than normal 6 (6.7)
3–4 stools more than normal 41 (45.6)
5 or more stools more than normal 43 (47.8)
Rectal bleeding, n (%)
No blood seen 6 (6.7)
Streaks of blood with stools less than half the time 27 (30.0)
Obvious blood with stool most of the time 37 (41.1)
Blood alone passed 20 (22.2)
Physician’s global assessment, n (%)
normal 0 (0.0)
Mild disease 4 (4.4)
Moderate disease 65 (72.2)
severe disease 21 (23.3)
Sigmoidoscopic/endoscopic findings, n (%)
normal or inactive disease 0 (0.0)
Mild disease 1 (1.1)
Moderate disease 54 (60.7)
severe disease 34 (38.2)
Abbreviations: UC, ulcerative colitis; TNF, tumor necrosis factor.
Table S3 Treatment-emergent adverse events










Injection-site hematoma Mild 1 1 day Yes none 6 days
Mild 1 2 days no none 12 days
Injection-site pain Mild 1 6 days Yes none Ongoing
Palpitations Mild 1 3 days no none 1 day
Flatulence Moderate 1 6 days no none 3 months
Dyspepsia Mild 1 10 days no Medication 3 months
UC flare Moderate 1 1 day Yes Medication 2 months
Viral upper respiratory tract infection Mild 1 1 day Yes none
headache Mild 1 3 days Yes Medication Ongoing
Hot flushes Mild 1 1 day Yes none Ongoing
Hemorrhoidal hemorrhage Mild 1 9 days no none Ongoing
Tooth sensitivity Mild 1 6 days Yes none Ongoing
Parotid gland enlargement Mild 1 12 days no Echography 1 month
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